StockWatch
·
KSB LTD · QQ1 FY-2027 · THE CALL

Weak Q1 masks long-term nuclear/infra tailwinds; near-term margin pressure

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q1 FY27 resultsKSBKSB Ltd26 Aug 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

Achieved 17% CAGR revenue and 22% CAGR PAT historically. Q1 miss is material—both revenue and profit below prior guidance; company defaulting to H2 recovery and long-term narrative.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

KSB delivered soft Q1 (3.6% revenue, -18.8% PAT) blamed on geopolitical crisis, supply-chain stress, and commodity inflation in fixed-price contracts. Management is defending near-term through cost control and hoping H2 recovery, but near-term visibility is weak and nuclear project execution is delayed. Long-term nuclear/data-centre tailwinds are real, but structural. Awaiting execution risk: GHAVP testing resolution, export clearance normalization, and competitor pressure on nuclear.

₹690.7 Cr

Revenue · +3.6% YoY

₹57.2 Cr

Reported PAT · −18.8% YoY

Compressing

Margins · vs guidance: Overstated

Did the claims hold up?

Management's claims vs. the numbers

Geopolitical crisis, supply chain issues temporary drivers of H1 weakness

Revenue +3.6% YoY despite claims of growth opportunities; OPM 11.8% vs 13-14% target

Partially Supported

Strong order intake growth and order book ₹27,445 Cr in June 2026

Order intake H1 FY27 ₹15,307 Cr (excluding nuclear) at 14% CAGR; reported but actual growth rate not disclosed

Unverified

Expected much better performance in H2 with export recovery

As of call (August), exports have not yet recovered; only inquiries and projects started, results awaited

MISS

Valves margin decline temporary; will return to double-digit

H1 valves margin fell to single-digit from mid-teens historically; company concedes need for sales recovery to normalize

OVERSTATED

Earnings quality

What changed since the last call

Deltas vs. the prior call

Export headwinds & supply-chain stress materialized

Downgrade

H1 exports faced geopolitical delays (war, tariffs); supply-chain issues cut production. 80-85% resolved now but full recovery delayed to H2. Inventory backlog still being diluted.

Solar business derailed; KUSUM 2.0 delayed

Downgrade

Solar revenue ₹50-60Cr (H1) vs expectations; only 5-7% of order book. Prior guidance implied stronger ramp. Scheme delay pushed recovery to Q3/Q4.

Valves margin collapse—not temporary

Downgrade

Valves fell to single-digit margins vs mid-teens historically. Company attributes to commodity costs & export mix but hasn't passed full costs to customers; mitigation vague.

Nuclear testing delays; GHAVP stalled

Downgrade

GHAVP testing hit issues at NPCIL test-bed (outside KSB's control). Testing now expected Sep 2026 onward. Revenue recognition pushed back further; execution risk remains on new tenders.

Full-year growth guidance softened

Neutral

Prior calls guided 15-20% revenue growth & 13-14% EBITDA. Now aiming for 'double-digit' (10%+) and 15-17% 'average,' more hedged. No explicit cut but tone is cautious.

The Q&A

Analysts pressed hard on margin compression (valves, foundry costs), project business slowdown, nuclear execution delays, and capex intensity. Management defended with temporary factors (geopolitical, supply chain) and H2 recovery hopes, but offered few quantitative commitments. Q&A showed skepticism on near-term visibility; management held firm on long-term positioning.

The exchanges that mattered

Macro growth & sector outlook — Saurabh Mehta, East Lane Capital

Answered

Energy (nuclear, conventional, renewable) leading; infrastructure (water, wastewater, airports, metros) secondary. Thermal 50GW under construction offers growth. Localization drives incremental opportunities.

Nuclear execution & competition — Saurabh Mehta, East Lane Capital

Partial

Kudankulam safety package on track; GHAVP testing stalled on NPCIL test-bed issues, resuming Sep. New tender 'next few months' for ~8 reactors. KSB is approved supplier; NPCIL decides competition.

H1 subdued performance — Shubham Murade, ICICI Securities

Answered

Geopolitical war halted export deliveries; ready pumps stuck. Supply chain issues resolved 80-85%. Data Centre growing globally; India focusing on liquid cooling, OEM orders emerging.

Nuclear pump execution cycle — Unidentified Analyst

Answered

Localization = parts previously imported now Made in India (mechanical seals, rotor parts, castings, Hurth gears). Design/tech from parent. Kudankulam redesigned in India due to geopolitical shifts.

Nuclear pump execution cycle & timeline — Unidentified Analyst

Answered

Standard cycle 24-36 months; deliveries to NPCIL ~48 months from order. Primary coolant pump ordered early (with steam generator). Testing dependent on NPCIL test-bed.

Valves margin collapse — Unidentified Analyst

Partial

Commodity prices, product mix, exports down, sales down. Combination of factors. Temporary; expect double-digit margin once sales recover and situation normalizes.

Solar business & KUSUM 2.0 — Unidentified Analyst

Answered

Solar H1 ₹50-60Cr (much below expectations) due to KUSUM 2.0 delayed to Q4. Got Maharashtra tender orders; expect pickup in Q3. Only 5-7% of order book vs 10-12% target.

Order intake growth slowdown — Mohit Surana, Monarch Networth Capital

Answered

Standard business growing but takes time (new markets: fire-fighting, marine, mining). Project market (oil & gas, petrochemical) slowed. Water/wastewater re-entering after years; product development underway. Supercritical thermal breakthrough (boiler circulation pump localized). Selective approach.

Full-year growth guidance — Mohit Surana, Monarch Networth Capital

Partial

Goal is double-digit growth. Nuclear testing delay a risk but low. Average 15-17% reasonable; 20% possible but peaky and unreliable. 10-15% volume, 15% value a good base.

Gas/commodity cost pass-through — Mohit Surana, Monarch Networth Capital

Answered

Foundries given 12-15% price increases; company passing single-digit to customers (phased). Margins under pressure 3-6 months lag. 85-90% supply stability now; cost agreements settled.

BP&CL integration & trajectory — Unidentified Analyst

Partial

PSU business requires proven track record (PTR), public tendering (GeM portal). Building inroads to ONGC, Oil India. Reciprocating pump EIL approval being pursued. Medium-term target ₹40-50Cr annually. Takes time in Indian PSU context.

SupremeServ aftermarket growth — Unidentified Analyst

Answered

Dedicated Chinchwad facility; warehouse for spare parts giving steady monthly revenue. Boiler circulation pump refurbishment orders started (new). Descaling pump localization orders (Japanese suppliers being replaced). Growing 15% p.a. Target 25-30% revenue share (excluding agri, lower is ok vs global 35%).

Export performance & order book — Unidentified Analyst

Partial

Current order book ~15% of sales (target 20%). Potential high but geopolitical disruptions (US tariffs, Middle East war) unpredictable. US boiler feed pumps for gas power plants, Middle East API leader, desalination market potential.

Receivables days trend — Unidentified Analyst

Answered

Solar business caused spike (state government payment lags, fund availability). Expect good momentum in H2 but won't improve dramatically (average metric). Documentation/fund availability dependent.

JJM water scheme & BP&CL track — Unidentified Analyst

Partial

JJM: positivity but still struggling on past projects; not yet visible. BP&CL: on track; PSU business takes time; building step-by-step. Targeting ₹40-50Cr annually.

Engineered pumps & project decline — Unidentified Analyst

Partial

First half slow on project pumps; many projects waiting to finalize (temporary). Inventory mainly export orders awaiting clearance, FGD business closure, solar slowdown. Not nuclear. Will be diluted.

HANA implementation risk — Unidentified Analyst

Partial

S/4HANA mandatory; will improve internal efficiency, remove workarounds. Lift-and-shift phase then innovation. OpEx impact next year (shared with group). Not quantified; board to approve.

Guidance

Forward guidance and management's confidence

Double-digit growth for full year; 15-17% average reasonable; 20% possible but peaky

Medium

Aiming for but hedged due to nuclear delays, export recovery uncertainty, and project finalization lag. H2 expected much better. Risks: GHAVP testing resolution, new tender timing.

EBITDA margins target 13-14%; maintained

Low

H1 OPM 11.8% vs target. Company cites temporary factors (commodity inflation, fixed contracts). Expects mitigation through higher sales volume and cost reduction. Timeline not specified.

Annual CapEx ₹80-100-120Cr (sustenance + growth); nuclear capacity +20% at Shirwal

High

Mix of machine replacement, nuclear/product development, office upgrades for employee engagement. Annual run-rate committed.

Risks the call surfaced

Ranked by how much they should concern a holder

Nuclear execution

High

GHAVP primary coolant pump testing stalled due to NPCIL test-bed issues. Testing delayed to September. Revenue recognition pushed back. New tender timing uncertain.

Margin compression

High

Fixed-price project contracts under pressure from foundry cost inflation (12-15% hikes). Company only passing single-digit increases to customers in standard business. Gross margins compressed; OpEx also hit.

Export disruption

High

H1 exports suffered from geopolitical crisis (war). Ready-for-delivery pumps stuck. Supply-chain issues (85-90% resolved) still impacting delivery. Inventory backlog ₹15-20Cr being diluted. Export order book recovery timing uncertain.

Valves margin collapse

Medium

Valves division margin fell to single-digit (from mid-teens historically) due to commodity prices, product mix, and export volume decline. Company attributes to temporary factors but timing for recovery vague.

Solar business slowdown

Medium

KUSUM 2.0 scheme delayed to Q4; H1 solar revenue ₹50-60Cr (5-7% of order book) vs expectations of 10-12% target share. Product development time required for new segments. Receivables days impacted by state government payment lags.

Nuclear competition

Medium

Analyst question on Kirloskar Brothers and Flowserve entering primary coolant pump space. NPCIL approval not exclusive; new tenders may introduce competition. KSB has 47 years experience and learning curve advantage but not guaranteed monopoly.

Management

Score 6/10. Transparent on headwinds (geopolitical, supply-chain, commodity inflation) but overly reliant on 'temporary' narrative. Specific numbers on cost recovery and margin timelines sparse. Open Q&A but deflects on quantitative guidance. Historical 17% CAGR revenue, 22% CAGR PAT but Q1 missed guidance badly (3.6% revenue, -18.8% PAT). Nuclear project delays show execution dependency on external partners. Supply-chain stabilization claims partially validated (80-85% done).

What to watch next
  • 1 · August 2026 (now)

    GHAVP nuclear pump testing expected to resume after test-bed issue resolution

  • 2 · September 2026

    GHAVP 500-hour pump test cycle begins; 2-3 month duration to validation & dispatch

  • 3 · Next few months

    New nuclear tender for 8 reactors (Mahi Banswara, Ashvini JV) expected; KSB is approved supplier

Awaiting execution risk: GHAVP testing resolution, export clearance normalization, and competitor pressure on nuclear.

Informational and educational content only. Not investment advice.